Population: individuals aged 40-70 years old diagnosed with advanced adenoma within less than one year from a clinical trial (17)Intervention: MUC1 peptide vaccine at 0, 2, and 10 weeks then booster dose at53 weeks. The gene discussed is MUC1; the disease is adenoma.